Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects

Ormutivimab is the first recombinant human anti-rabies monoclonal antibody (rhRIG) approved for clinical application in China. In this study, a population pharmacodynamic (PPD) model was established to compare the neutralizing antibody activities of Ormutivimab and human rabies immunoglobulin (HRIG)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Junnan, Shi, Nianmin, Li, Guohua, Li, Li, Bai, Yunhua, Yang, Liqing, Zhao, Weimin, Gao, Jian, Wei, Jingshuang, Zhao, Wei, Zhai, Lili, Huo, Peiyuan, Ren, Lemin, Yu, Lan, Li, Yufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415024/
https://www.ncbi.nlm.nih.gov/pubmed/36016106
http://dx.doi.org/10.3390/vaccines10081218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415024/
https://www.ncbi.nlm.nih.gov/pubmed/36016106
http://dx.doi.org/10.3390/vaccines10081218

Ejemplares similares